Skin Cancer | Topics

 
Cemiplimab Shows Clinical Benefit for BCC After Hedgehog Inhibitor Therapy
July 31, 2021

Cemiplimab for patients with either metastatic or locally advanced basal cell carcinoma showed antitumor activity in a phase 2 trial.

FDA Expands Indication for Pembrolizumab in Locally Advanced CSCC
July 06, 2021

Pembrolizumab has been granted an expanded indication by the FDA for locally advanced cutaneous squamous cell carcinoma.

Pembrolizumab Induces Robust, Durable Antitumor Activity in Advanced CSCC
April 11, 2021

These data establish pembrolizumab as a promising treatment option for those with locally advanced and recurrent/metastatic cutaneous squamous cell carcinoma, according to Brett G.M. Hughes, MD.